Top

Published in:

Open Access 01-05-2022 | Osteoporosis | Review

Early-Onset Osteoporosis

Authors: Outi Mäkitie, M. Carola Zillikens

Published in: Calcified Tissue International | Issue 5/2022

Abstract

Osteoporosis is a skeletal disorder with enhanced bone fragility, usually affecting the elderly. It is very rare in children and young adults and the definition is not only based on a low BMD (a Z-score < − 2.0 in growing children and a Z-score ≤ − 2.0 or a T-score ≤ − 2.5 in young adults) but also on the occurrence of fragility fractures and/or the existence of underlying chronic diseases or secondary factors such as use of glucocorticoids. In the absence of a known chronic disease, fragility fractures and low BMD should prompt extensive screening for secondary causes, which can be found in up to 90% of cases. When fragility fractures occur in childhood or young adulthood without an evident secondary cause, investigations should explore the possibility of an underlying monogenetic bone disease, where bone fragility is caused by a single variant in a gene that has a major role in the skeleton. Several monogenic forms relate to type I collagen, but other forms also exist. Loss-of-function variants in LRP5 and WNT1 may lead to early-onset osteoporosis. The X-chromosomal osteoporosis caused by PLS3 gene mutations affects especially males. Another recently discovered form relates to disturbed sphingolipid metabolism due to SGMS2 mutations, underscoring the complexity of molecular pathology in monogenic early-onset osteoporosis. Management of young patients consists of treatment of secondary factors, optimizing lifestyle factors including calcium and vitamin D and physical exercise. Treatment with bone-active medication should be discussed on a personalized basis, considering the severity of osteoporosis and underlying disease versus the absence of evidence on anti-fracture efficacy and potential harmful effects in pregnancy.

Kanis JA, Gluer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors International Osteoporosis Foundation. Osteoporos Int 11:192–202CrossRefPubMed

Mäkitie RE, Costantini A, Kämpe A, Alm JJ, Mäkitie O (2019) New insights into monogenic causes of osteoporosis. Front Endocrinol (Lausanne) 25(10):70. https://doi.org/10.3389/fendo.2019.00070CrossRef

Mäkitie O (2013) Causes, mechanisms and management of paediatric osteoporosis. Nat Rev Rheumatol 9(8):465–475. https://doi.org/10.1038/nrrheum.2013.45CrossRefPubMed

Chotiyarnwong P, McCloskey EV (2020) Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol 16(8):437–447. https://doi.org/10.1038/s41574-020-0341-0CrossRefPubMed

Galindo-Zavala R, Bou-Torrent R, Magallares-López B, Mir-Perelló C, Palmou-Fontana N, Sevilla-Pérez B, Medrano-San Ildefonso M, González-Fernández MI, Román-Pascual A, Alcañiz-Rodríguez P, Nieto-Gonzalez JC, López-Corbeto M, Graña-Gil J (2020) Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol Online J 18(1):20. https://doi.org/10.1186/s12969-020-0411-9CrossRefPubMedPubMedCentral

Laakso S, Valta H, Verkasalo M, Toiviainen-Salo S, Mäkitie O (2014) Compromised peak bone mass in patients with inflammatory bowel disease—a prospective study. J Pediatr 164(6):1436–43.e1. https://doi.org/10.1016/j.jpeds.2014.01.073CrossRefPubMed

Golden NH, Abrams SA, Committee on Nutrition (2014) Optimizing bone health in children and adolescents. Pediatrics 134(4):e1229-43. https://doi.org/10.1542/peds.2014-2173CrossRefPubMed

Zhu X, Zheng H (2021) Factors influencing peak bone mass gain. Front Med 15(1):53–69. https://doi.org/10.1007/s11684-020-0748-yCrossRefPubMed

Rahaman SH, Jyotsna VP, Kandasamy D, Shreenivas V, Gupta N, Tandon N (2018) Bone health in patients with Cushing’s syndrome. Indian J Endocrinol Metab 22(6):766–769CrossRefPubMedPubMedCentral

10.

Cairoli E, Eller-Vainicher C, Morlacchi LC, Tarsia P, Rossetti V, Pappalettera M, Arosio M, Chiodini I, Blasi F (2019) Bone involvement in young adults with cystic fibrosis awaiting lung transplantation for end-stage respiratory failure. Osteoporos Int 30(6):1255–1263CrossRefPubMed

11.

Weaver CM, Gordon CM, Janz KF, Kalkwarf HJ, Lappe JM, Lewis R, O’Karma M, Wallace TC, Zemel BS (2016) The National Osteoporosis Foundation’s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int 27(4):1281–1386. https://doi.org/10.1007/s00198-015-3440-3 (Erratum in: Osteoporos Int. 2016 Apr;27(4):1387)CrossRefPubMedPubMedCentral

12.

Berger C, Goltzman D, Langsetmo L, Joseph L, Jackson S, Kreiger N, Tenenhouse A, Davison KS, Josse RG, Prior JC, Hanley DA (2010) Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res 25:1948–1957CrossRefPubMed

13.

Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, Kalkwarf HJ, Langman CB, Plotkin H, Rauch F, Zemel BS, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S (2008) International society for clinical densitometry 2007 adult and pediatric official positions. Bone 43(6):1115–1121. https://doi.org/10.1016/j.bone.2008.08.106CrossRefPubMed

14.

Ferrari S, Bianchi ML, Eisman JA, Foldes AJ, Adami S, Wahl DA, Stepan JJ, de Vernejoul MC, Kaufman JM, IOF Committee of Scientific Advisors Working Group on Osteoporosis Pathophysiology (2012) Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 23(12):2735–48. https://doi.org/10.1007/s00198-012-2030-xCrossRefPubMed

15.

Mäyränpää MK, Viljakainen HT, Toiviainen-Salo S, Kallio PE, Mäkitie O (2012) Impaired bone health and asymptomatic vertebral compressions in fracture-prone children: a case-control study. J Bone Miner Res 27(6):1413–1424. https://doi.org/10.1002/jbmr.1579CrossRefPubMed

16.

Whyte MP (2016) Hypophosphatasia—aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 12(4):233–246. https://doi.org/10.1038/nrendo.2016.14CrossRefPubMed

17.

Hannan FM, Newey PJ, Whyte MP, Thakker RV (2019) Genetic approaches to metabolic bone diseases. Br J Clin Pharmacol 85(6):1147–1160. https://doi.org/10.1111/bcp.13803CrossRefPubMed

18.

Ferrari SL, Deutsch S, Baudoin C, Cohen-Solal M, Ostertag A, Antonarakis SE, Rizzoli R, de Vernejoul MC (2005) LRP5 gene polymorphisms and idiopathic osteoporosis in men. Bone 37(6):770–775CrossRefPubMed

19.

Pepe J, Body JJ, Hadji P, McCloskey E, Meier C, Obermayer-Pietsch B, Palermo A, Tsourdi E, Zillikens MC, Langdahl B, Ferrari S (2020) Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOF. J Clin Endocrinol Metab 105(8):dgaa306. https://doi.org/10.1210/clinem/dgaa306CrossRefPubMed

20.

Yao L, Wang H, Dong W, Liu Z, Mao H (2017) Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease: a meta-analysis. Medicine (Baltimore) 96(3):e5861. https://doi.org/10.1097/MD.0000000000005861CrossRef

21.

Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE (2017) Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1–12. https://doi.org/10.1016/j.jbo.2017.03.001CrossRefPubMedPubMedCentral

22.

Kyvernitakis I, Kostev K, Hadji P (2018) The tamoxifen paradoxinfluence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer. Osteoporos Int 29(11):2557–2564CrossRefPubMed

23.

Waqas K, Ferreira JL, Tsourdi E, Body J, Hadji P, Zillikens M.C. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol 2021, in press

24.

Solmi M, Veronese N, Correll CU, Favaro A, Santonastaso P, Caregaro L, Vancampfort D, Luchini C, De Hert M, Stubbs B (2016) Bone mineral density, osteoporosis, and fractures among people with eating disorders: a systematic review and meta-analysis. Acta Psychiatr Scand 133(5):341–351CrossRefPubMed

25.

Miller KK, Grinspoon SK, Ciampa J et al (2005) Medical findings in outpatients with anorexia nervosa. Arch Intern Med 165(5):561–566CrossRefPubMed

26.

Miller KK (2013) Endocrine effects of anorexia nervosa. Endocrinol Metab Clin North Am 42(3):515–528. https://doi.org/10.1016/j.ecl.2013.05.007CrossRefPubMedPubMedCentral

27.

Robinson L, Aldridge V, Clark EM, Misra M, Micali N (2017) Pharmacological treatment options for low bone mineral density and secondary osteoporosis in anorexia nervosa: a systematic review of the literature. J Psychosom Res 98:87–97. https://doi.org/10.1016/j.jpsychores.2017.05.011CrossRefPubMedPubMedCentral

28.

De Souza MJ, Nattiv A, Joy E (2014) Expert panel, 2014 Female athlete triad coalition consensus statement on treatment and return to play of the female athlete triad: 1st international conference held in San Francisco, California, May 2012 and 2nd international conference held in Indianapolis, Indiana, May 2013. Br J Sports Med 48:289. https://doi.org/10.1136/bjsports-2013-093218CrossRefPubMed

29.

Buckley L, Humphrey MB (2018) Glucocorticoid-induced osteoporosis. N Engl J Med 379(26):2547–2556CrossRefPubMed

30.

LeBlanc CM, Ma J, Taljaard M, Roth J, Scuccimarri R, Miettunen P, Lang B, Huber AM, Houghton K, Jaremko JL, Ho J, Shenouda N, Matzinger MA, Lentle B, Stein R, Sbrocchi AM, Oen K, Rodd C, Jurencak R, Cummings EA, Couch R, Cabral DA, Atkinson S, Alos N, Rauch F, Siminoski K, Ward LM, Canadian STeroid-Associated Osteoporosis in Pediatric Population (STOPP) Consortium (2015) Incident vertebral fractures and risk factors in the first three years following glucocorticoid initiation among pediatric patients with rheumatic disorders. J Bone Miner Res 30(9):1667–75. https://doi.org/10.1002/jbmr.2511CrossRefPubMed

31.

Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T (2017) 2017 American College of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 69(8):1521–1537. https://doi.org/10.1002/art.40137CrossRefPubMed

32.

Kyvernitakis I, Reuter TC, Hellmeyer L, Hars O, Hadji P (2018) Subsequent fracture risk of women with pregnancy and lactation-associated osteoporosis after a median of 6 years of follow-up. Osteoporos Int 29(1):135–142. https://doi.org/10.1007/s00198-017-4239-1CrossRefPubMed

33.

Cohen A, Kamanda-Kosseh M, Dempster DW, Zhou H, Müller R, Goff E, Colon I, Bucovsky M, Stubby J, Nickolas TL, Stein EM, Recker RR, Lappe JM, Shane E (2019) Women with pregnancy and lactation-associated osteoporosis (PLO) have low bone remodeling rates at the tissue level. J Bone Miner Res 34(9):1552–1561CrossRefPubMed

34.

Campos-Obando N, Oei L, Hoefsloot LH, Kiewiet RM, Klaver CC, Simon ME, Zillikens MC (2014) Osteoporotic vertebral fractures during pregnancy: be aware of a potential underlying genetic cause. J Clin Endocrinol Metab 99(4):1107–1111. https://doi.org/10.1210/jc.2013-3238CrossRefPubMed

35.

Ostertag A, Cohen-Solal M, Audran M, Legrand E, Marty C, Chappard D, de Vernejoul MC (2009) Vertebral fractures are associated with increased cortical porosity in iliac crest bone biopsy of men with idiopathic osteoporosis. Bone 44(3):413–417CrossRefPubMed

36.

Rolvien T, Stürznickel J, Schmidt FN, Butscheidt S, Schmidt T, Busse B, Mundlos S, Schinke T, Kornak U, Amling M, Oheim R (2018) Comparison of bone microarchitecture between adult osteogenesis imperfecta and early-onset osteoporosis. Calcif Tissue Int 103(5):512–521CrossRefPubMed

37.

Collet C, Ostertag A, Ricquebourg M, Delecourt M, Tueur G, Isidor B, Guillot P, Schaefer E, Javier RM, Funck-Brentano T, Orcel P, Laplanche JL, Cohen-Solal M (2017) Primary osteoporosis in young adults: genetic basis and identification of novel variants in causal genes. JBMR Plus 2(1):12–21CrossRefPubMedPubMedCentral

38.

Hartikka H, Mäkitie O, Männikkö M, Doria AS, Daneman A, Cole WG, Ala-Kokko L, Sochett EB (2005) Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res 20(5):783–789. https://doi.org/10.1359/JBMR.050101CrossRefPubMed

39.

Arnold A, Dennison E, Kovacs CS, Mannstadt M, Rizzoli R, Brandi ML, Clarke B, Thakker RV (2021) Hormonal regulation of biomineralization. Nat Rev Endocrinol. https://doi.org/10.1038/s41574-021-00477-2CrossRefPubMed

40.

Marini JC, Forlino A, Bächinger HP, Bishop NJ, Byers PH, Paepe A, Fassier F, Fratzl-Zelman N, Kozloff KM, Krakow D, Montpetit K, Semler O (2017) Osteogenesis imperfecta. Nat Rev Dis Primers 18(3):17052. https://doi.org/10.1038/nrdp.2017.52CrossRef

41.

Cundy T (2012) Recent advances in osteogenesis imperfecta. Calcif Tissue Int 90(6):439–449. https://doi.org/10.1007/s00223-012-9588-3CrossRefPubMed

42.

Besio R, Chow CW, Tonelli F, Marini JC, Forlino A (2019) Bone biology: insights from osteogenesis imperfecta and related rare fragility syndromes. FEBS J 286(15):3033–3056. https://doi.org/10.1111/febs.14963CrossRefPubMedPubMedCentral

43.

Huybrechts Y, Mortier G, Boudin E, Van Hul W (2020) WNT signaling and bone: lessons from skeletal dysplasias and disorders. Front Endocrinol (Lausanne) 9(11):165. https://doi.org/10.3389/fendo.2020.00165CrossRef

44.

Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Jüppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML, Osteoporosis-Pseudoglioma Syndrome Collaborative Group (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 107(4):513–23. https://doi.org/10.1016/s0092-8674(01)00571-2CrossRefPubMed

45.

Laine CM, Joeng KS, Campeau PM, Kiviranta R, Tarkkonen K, Grover M, Lu JT, Pekkinen M, Wessman M, Heino TJ, Nieminen-Pihala V, Aronen M, Laine T, Kröger H, Cole WG, Lehesjoki AE, Nevarez L, Krakow D, Curry CJ, Cohn DH, Gibbs RA, Lee BH, Mäkitie O (2013) WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med 368(19):1809–1816. https://doi.org/10.1056/NEJMoa1215458CrossRefPubMedPubMedCentral

46.

Mäkitie RE, Haanpää M, Valta H, Pekkinen M, Laine CM, Lehesjoki AE, Schalin-Jäntti C, Mäkitie O (2016) Skeletal characteristics of WNT1 osteoporosis in children and young adults. J Bone Miner Res 31(9):1734–1742. https://doi.org/10.1002/jbmr.2841CrossRefPubMed

47.

Stürznickel J, Rolvien T, Delsmann A, Butscheidt S, Barvencik F, Mundlos S, Schinke T, Kornak U, Amling M, Oheim R (2021) Clinical phenotype and relevance of LRP5 and LRP6 variants in patients with early-onset osteoporosis (EOOP). J Bone Miner Res 36(2):271–282. https://doi.org/10.1002/jbmr.4197CrossRefPubMed

48.

Somer H, Palotie A, Somer M, Hoikka V, Peltonen L (1988) Osteoporosis-pseudoglioma syndrome: clinical, morphological, and biochemical studies. J Med Genet 25(8):543–549. https://doi.org/10.1136/jmg.25.8.543CrossRefPubMedPubMedCentral

49.

Saarinen A, Välimäki VV, Välimäki MJ, Löyttyniemi E, Auro K, Uusen P, Kuris M, Lehesjoki AE, Mäkitie O (2007) The A1330V polymorphism of the low-density lipoprotein receptor-related protein 5 gene (LRP5) associates with low peak bone mass in young healthy men. Bone 40(4):1006–1012. https://doi.org/10.1016/j.bone.2006.11.010CrossRefPubMed

50.

Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, Ntzani EE, Oei L, Albagha OM, Amin N, Kemp JP, Koller DL, Li G, Liu CT, Minster RL, Moayyeri A, Vandenput L, Willner D, Xiao SM, Yerges-Armstrong LM, Zheng HF, Alonso N, Eriksson J, Kammerer CM, Kaptoge SK, Leo PJ, Thorleifsson G, Wilson SG, Wilson JF, Aalto V, Alen M, Aragaki AK, Aspelund T, Center JR, Dailiana Z, Duggan DJ, Garcia M, Garcia-Giralt N, Giroux S, Hallmans G, Hocking LJ, Husted LB, Jameson KA, Khusainova R, Kim GS, Kooperberg C, Koromila T, Kruk M, Laaksonen M, Lacroix AZ, Lee SH, Leung PC, Lewis JR, Masi L, Mencej-Bedrac S, Nguyen TV, Nogues X, Patel MS, Prezelj J, Rose LM, Scollen S, Siggeirsdottir K, Smith AV, Svensson O, Trompet S, Trummer O, van Schoor NM, Woo J, Zhu K, Balcells S, Brandi ML, Buckley BM, Cheng S, Christiansen C, Cooper C, Dedoussis G, Ford I, Frost M, Goltzman D, González-Macías J, Kähönen M, Karlsson M, Khusnutdinova E, Koh JM, Kollia P, Langdahl BL, Leslie WD, Lips P, Ljunggren Ö, Lorenc RS, Marc J, Mellström D, Obermayer-Pietsch B, Olmos JM, Pettersson-Kymmer U, Reid DM, Riancho JA, Ridker PM, Rousseau F, Slagboom PE, Tang NL, Urreizti R, Van Hul W, Viikari J, Zarrabeitia MT, Aulchenko YS, Castano-Betancourt M, Grundberg E, Herrera L, Ingvarsson T, Johannsdottir H, Kwan T, Li R, Luben R, Medina-Gómez C, Palsson ST, Reppe S, Rotter JI, Sigurdsson G, van Meurs JB, Verlaan D, Williams FM, Wood AR, Zhou Y, Gautvik KM, Pastinen T, Raychaudhuri S, Cauley JA, Chasman DI, Clark GR, Cummings SR, Danoy P, Dennison EM, Eastell R, Eisman JA, Gudnason V, Hofman A, Jackson RD, Jones G, Jukema JW, Khaw KT, Lehtimäki T, Liu Y, Lorentzon M, McCloskey E, Mitchell BD, Nandakumar K, Nicholson GC, Oostra BA, Peacock M, Pols HA, Prince RL, Raitakari O, Reid IR, Robbins J, Sambrook PN, Sham PC, Shuldiner AR, Tylavsky FA, van Duijn CM, Wareham NJ, Cupples LA, Econs MJ, Evans DM, Harris TB, Kung AW, Psaty BM, Reeve J, Spector TD, Streeten EA, Zillikens MC, Thorsteinsdottir U, Ohlsson C, Karasik D, Richards JB, Brown MA, Stefansson K, Uitterlinden AG, Ralston SH, Ioannidis JP, Kiel DP, Rivadeneira F (2012) Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 44(5):491–501. https://doi.org/10.1038/ng.2249CrossRefPubMedPubMedCentral

51.

Wang QF, Bi HS, Qin ZL, Wang P, Nie FF, Zhang GW (2020) Associations of LRP5 gene with bone mineral density, bone turnover markers, and fractures in the elderly with osteoporosis. Front Endocrinol (Lausanne) 25(11):571549. https://doi.org/10.3389/fendo.2020.571549CrossRef

52.

Tüysüz B, Bursalı A, Alp Z, Suyugül N, Laine CM, Mäkitie O (2012) Osteoporosis-pseudoglioma syndrome: three novel mutations in the LRP5 gene and response to bisphosphonate treatment. Horm Res Paediatr 77(2):115–120. https://doi.org/10.1159/000336193CrossRefPubMed

53.

Papadopoulos I, Bountouvi E, Attilakos A, Gole E, Dinopoulos A, Peppa M, Nikolaidou P, Papadopoulou A (2019) Osteoporosis-pseudoglioma syndrome: clinical, genetic, and treatment-response study of 10 new cases in Greece. Eur J Pediatr 178(3):323–329. https://doi.org/10.1007/s00431-018-3299-3CrossRefPubMed

54.

Marozik P, Alekna V, Rudenko E, Tamulaitiene M, Rudenka A, Mastaviciute A, Samokhovec V, Cernovas A, Kobets K, Mosse I (2019) Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis. PLoS ONE 14(8):e0221511. https://doi.org/10.1371/journal.pone.0221511CrossRefPubMedPubMedCentral

55.

Kruk M, Ralston SH, Albagha OM (2009) LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men. Calcif Tissue Int 84(3):171–179. https://doi.org/10.1007/s00223-008-9207-5CrossRefPubMed

56.

Saarinen A, Saukkonen T, Kivelä T, Lahtinen U, Laine C, Somer M, Toiviainen-Salo S, Cole WG, Lehesjoki AE, Mäkitie O (2010) Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia. Clin Endocrinol (Oxf) 72(4):481–488. https://doi.org/10.1111/j.1365-2265.2009.03680.xCrossRef

57.

Kim SP, Frey JL, Li Z, Goh BC, Riddle RC (2017) Lack of Lrp5 signaling in osteoblasts sensitizes male mice to diet-induced disturbances in glucose metabolism. Endocrinology 158(11):3805–3816. https://doi.org/10.1210/en.2017-00657CrossRefPubMedPubMedCentral

58.

Foer D, Zhu M, Cardone RL, Simpson C, Sullivan R, Nemiroff S, Lee G, Kibbey RG, Petersen KF, Insogna KL (2017) Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis. Osteoporos Int 28(6):2011–2017. https://doi.org/10.1007/s00198-017-3977-4CrossRefPubMedPubMedCentral

59.

Korvala J, Jüppner H, Mäkitie O, Sochett E, Schnabel D, Mora S, Bartels CF, Warman ML, Deraska D, Cole WG, Hartikka H, Ala-Kokko L, Männikkö M (2012) Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med Genet 10(13):26. https://doi.org/10.1186/1471-2350-13-26CrossRef

60.

Witte F, Dokas J, Neuendorf F, Mundlos S, Stricker S (2009) Comprehensive expression analysis of all Wnt genes and their major secreted antagonists during mouse limb development and cartilage differentiation. Gene Expr Patterns 9(4):215–223. https://doi.org/10.1016/j.gep.2008.12.009CrossRefPubMed

61.

Movérare-Skrtic S, Henning P, Liu X, Nagano K, Saito H, Börjesson AE, Sjögren K, Windahl SH, Farman H, Kindlund B, Engdahl C, Koskela A, Zhang FP, Eriksson EE, Zaman F, Hammarstedt A, Isaksson H, Bally M, Kassem A, Lindholm C, Sandberg O, Aspenberg P, Sävendahl L, Feng JQ, Tuckermann J, Tuukkanen J, Poutanen M, Baron R, Lerner UH, Gori F, Ohlsson C (2014) Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures. Nat Med 20(11):1279–88. https://doi.org/10.1038/nm.3654CrossRefPubMedPubMedCentral

62.

Zheng HF, Tobias JH, Duncan E, Evans DM, Eriksson J, Paternoster L, Yerges-Armstrong LM, Lehtimäki T, Bergström U, Kähönen M, Leo PJ, Raitakari O, Laaksonen M, Nicholson GC, Viikari J, Ladouceur M, Lyytikäinen LP, Medina-Gomez C, Rivadeneira F, Prince RL, Sievanen H, Leslie WD, Mellström D, Eisman JA, Movérare-Skrtic S, Goltzman D, Hanley DA, Jones G, St Pourcain B, Xiao Y, Timpson NJ, Smith GD, Reid IR, Ring SM, Sambrook PN, Karlsson M, Dennison EM, Kemp JP, Danoy P, Sayers A, Wilson SG, Nethander M, McCloskey E, Vandenput L, Eastell R, Liu J, Spector T, Mitchell BD, Streeten EA, Brommage R, Pettersson-Kymmer U, Brown MA, Ohlsson C, Richards JB, Lorentzon M (2012) WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet 8(7):e1002745. https://doi.org/10.1371/journal.pgen.1002745CrossRefPubMedPubMedCentral

63.

Gori F, Lerner U, Ohlsson C, Baron R (2015) A new WNT on the bone: WNT16, cortical bone thickness, porosity and fractures. Bonekey Rep 13(4):669. https://doi.org/10.1038/bonekey.2015.36CrossRef

64.

Medina-Gomez C, Kemp JP, Estrada K, Eriksson J, Liu J, Reppe S, Evans DM, Heppe DH, Vandenput L, Herrera L, Ring SM, Kruithof CJ, Timpson NJ, Zillikens MC, Olstad OK, Zheng HF, Richards JB, St Pourcain B, Hofman A, Jaddoe VW, Smith GD, Lorentzon M, Gautvik KM, Uitterlinden AG, Brommage R, Ohlsson C, Tobias JH, Rivadeneira F (2012) Meta-analysis of genome-wide scans for total body BMD in children and adults reveals allelic heterogeneity and age-specific effects at the WNT16 locus. PLoS Genet. 8(7):e1002718. https://doi.org/10.1371/journal.pgen.1002718CrossRefPubMedPubMedCentral

65.

Keupp K, Beleggia F, Kayserili H, Barnes AM, Steiner M, Semler O, Fischer B, Yigit G, Janda CY, Becker J, Breer S, Altunoglu U, Grünhagen J, Krawitz P, Hecht J, Schinke T, Makareeva E, Lausch E, Cankaya T, Caparrós-Martín JA, Lapunzina P, Temtamy S, Aglan M, Zabel B, Eysel P, Koerber F, Leikin S, Garcia KC, Netzer C, Schönau E, Ruiz-Perez VL, Mundlos S, Amling M, Kornak U, Marini J, Wollnik B (2013) Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet 92(4):565–74. https://doi.org/10.1016/j.ajhg.2013.02.010CrossRefPubMedPubMedCentral

66.

Pyott SM, Tran TT, Leistritz DF, Pepin MG, Mendelsohn NJ, Temme RT, Fernandez BA, Elsayed SM, Elsobky E, Verma I, Nair S, Turner EH, Smith JD, Jarvik GP, Byers PH (2013) WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet 92(4):590–597. https://doi.org/10.1016/j.ajhg.2013.02.009CrossRefPubMedPubMedCentral

67.

Nampoothiri S, Guillemyn B, Elcioglu N, Jagadeesh S, Yesodharan D, Suresh B, Turan S, Symoens S, Malfait F (2019) Ptosis as a unique hallmark for autosomal recessive WNT1-associated osteogenesis imperfecta. Am J Med Genet A 179(6):908–914. https://doi.org/10.1002/ajmg.a.61119CrossRefPubMed

68.

Hayat A, Hussain S, Bilal M, Kausar M, Almuzzaini B, Abbas S, Tanveer A, Khan A, Siddiqi S, Foo JN, Ahmad F, Khan F, Khan B, Anees M, Mäkitie O, Alfadhel M, Ahmad W, Umair M (2020) Biallelic variants in four genes underlying recessive osteogenesis imperfecta. Eur J Med Genet. 63(8):103954. https://doi.org/10.1016/j.ejmg.2020.103954CrossRefPubMed

69.

Kausar M, Siddiqi S, Yaqoob M, Mansoor S, Makitie O, Mir A, Khor CC, Foo JN, Anees M (2018) Novel mutation G324C in WNT1 mapped in a large Pakistani family with severe recessively inherited Osteogenesis Imperfecta. J Biomed Sci 25(1):82. https://doi.org/10.1186/s12929-018-0481-x (Erratum in: J Biomed Sci. 2019 Apr 28;26(1):31)CrossRefPubMedPubMedCentral

70.

Umair M, Alhaddad B, Rafique A, Jan A, Haack TB, Graf E, Ullah A, Ahmad F, Strom TM, Meitinger T, Ahmad W (2017) Exome sequencing reveals a novel homozygous splice site variant in the WNT1 gene underlying osteogenesis imperfecta type 3. Pediatr Res 82(5):753–758. https://doi.org/10.1038/pr.2017.149CrossRefPubMed

71.

Mäkitie RE, Niinimäki T, Nieminen MT, Schalin-Jäntti C, Niinimäki J, Mäkitie O (2017) Impaired WNT signaling and the spine-Heterozygous WNT1 mutation causes severe age-related spinal pathology. Bone 101:3–9. https://doi.org/10.1016/j.bone.2017.04.001CrossRefPubMed

72.

Wesseling-Perry K, Mäkitie RE, Välimäki VV, Laine T, Laine CM, Välimäki MJ, Pereira RC, Mäkitie O (2017) Osteocyte protein expression is altered in low-turnover osteoporosis caused by mutations in WNT1 and PLS3. J Clin Endocrinol Metab 102(7):2340–2348. https://doi.org/10.1210/jc.2017-00099CrossRefPubMedPubMedCentral

73.

Fratzl-Zelman N, Wesseling-Perry K, Mäkitie RE, Blouin S, Hartmann MA, Zwerina J, Välimäki VV, Laine CM, Välimäki MJ, Pereira RC, Mäkitie O (2021) Bone material properties and response to teriparatide in osteoporosis due to WNT1 and PLS3 mutations. Bone 146:115900. https://doi.org/10.1016/j.bone.2021.115900CrossRefPubMed

74.

Välimäki VV, Mäkitie O, Pereira R, Laine C, Wesseling-Perry K, Määttä J, Kirjavainen M, Viljakainen H, Välimäki MJ (2017) Teriparatide treatment in patients with WNT1 or PLS3 mutation-related early-onset osteoporosis: a pilot study. J Clin Endocrinol Metab 102(2):535–544. https://doi.org/10.1210/jc.2016-2423CrossRefPubMed

75.

Mäkitie RE, Niinimäki R, Kakko S, Honkanen T, Kovanen PE, Mäkitie O (2018) Defective WNT signaling associates with bone marrow fibrosis-a cross-sectional cohort study in a family with WNT1 osteoporosis. Osteoporos Int 29(2):479–487. https://doi.org/10.1007/s00198-017-4309-4CrossRefPubMed

76.

Mäkitie RE, Kämpe A, Costantini A, Alm JJ, Magnusson P, Mäkitie O (2020) Biomarkers in WNT1 and PLS3 osteoporosis: altered concentrations of DKK1 and FGF23. J Bone Miner Res 35(5):901–912. https://doi.org/10.1002/jbmr.3959CrossRefPubMed

77.

Joeng KS, Lee YC, Jiang MM, Bertin TK, Chen Y, Abraham AM, Ding H, Bi X, Ambrose CG, Lee BH (2014) The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations. Hum Mol Genet 23(15):4035–42. https://doi.org/10.1093/hmg/ddu117CrossRefPubMedPubMedCentral

78.

Joeng KS, Lee YC, Lim J, Chen Y, Jiang MM, Munivez E, Ambrose C, Lee BH (2017) Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis. J Clin Invest 127(7):2678–2688CrossRefPubMedPubMedCentral

79.

Lehtovirta S, Mäkitie RE, Casula V, Haapea M, Niinimäki J, Niinimäki T, Peuna A, Lammentausta E, Mäkitie O, Nieminen MT (2019) Defective WNT signaling may protect from articular cartilage deterioration—a quantitative MRI study on subjects with a heterozygous WNT1 mutation. Osteoarthritis Cartilage 27(11):1636–1646. https://doi.org/10.1016/j.joca.2019.07.001CrossRefPubMed

80.

van Dijk FS, Zillikens MC, Micha D, Riessland M, Marcelis CL, de Die-Smulders CE, Milbradt J, Franken AA, Harsevoort AJ, Lichtenbelt KD, Pruijs HE, Rubio-Gozalbo ME, Zwertbroek R, Moutaouakil Y, Egthuijsen J, Hammerschmidt M, Bijman R, Semeins CM, Bakker AD, Everts V, Klein-Nulend J, Campos-Obando N, Hofman A, te Meerman GJ, Verkerk AJ, Uitterlinden AG, Maugeri A, Sistermans EA, Waisfisz Q, Meijers-Heijboer H, Wirth B, Simon ME, Pals G (2013) PLS3 mutations in X-linked osteoporosis with fractures. N Engl J Med 369(16):1529–1536. https://doi.org/10.1056/NEJMoa1308223CrossRefPubMed

81.

Laine CM, Wessman M, Toiviainen-Salo S, Kaunisto MA, Mäyränpää MK, Laine T, Pekkinen M, Kröger H, Välimäki VV, Välimäki MJ, Lehesjoki AE, Mäkitie O (2015) A novel splice mutation in PLS3 causes X-linked early onset low-turnover osteoporosis. J Bone Miner Res 30(3):510–518. https://doi.org/10.1002/jbmr.2355CrossRefPubMed

82.

Kämpe AJ, Costantini A, Mäkitie RE, Jäntti N, Valta H, Mäyränpää M, Kröger H, Pekkinen M, Taylan F, Jiao H, Mäkitie O (2017) PLS3 sequencing in childhood-onset primary osteoporosis identifies two novel disease-causing variants. Osteoporos Int 28(10):3023–3032. https://doi.org/10.1007/s00198-017-4150-9CrossRefPubMedPubMedCentral

83.

Kämpe AJ, Costantini A, Levy-Shraga Y, Zeitlin L, Roschger P, Taylan F, Lindstrand A, Paschalis EP, Gamsjaeger S, Raas-Rothschild A, Hövel M, Jiao H, Klaushofer K, Grasemann C, Mäkitie O (2017) PLS3 deletions lead to severe spinal osteoporosis and disturbed bone matrix mineralization. J Bone Miner Res 32(12):2394–2404. https://doi.org/10.1002/jbmr.3233CrossRefPubMed

84.

Costantini A, Krallis PΝ, Kämpe A, Karavitakis EM, Taylan F, Mäkitie O, Doulgeraki A (2018) A novel frameshift deletion in PLS3 causing severe primary osteoporosis. J Hum Genet 63(8):923–926. https://doi.org/10.1038/s10038-018-0472-5CrossRefPubMed

85.

Costantini A, Skarp S, Kämpe A, Mäkitie RE, Pettersson M, Männikkö M, Jiao H, Taylan F, Lindstrand A, Mäkitie O (2018) Rare copy number variants in array-based comparative genomic hybridization in early-onset skeletal fragility. Front Endocrinol (Lausanne) 10(9):380. https://doi.org/10.3389/fendo.2018.00380CrossRef

86.

Balasubramanian M, Fratzl-Zelman N, O’Sullivan R, Bull M, Fa Peel N, Pollitt RC, Jones R, Milne E, Smith K, Roschger P, Klaushofer K, Bishop NJ (2018) Novel PLS3 variants in X-linked osteoporosis: exploring bone material properties. Am J Med Genet A 176(7):1578–1586. https://doi.org/10.1002/ajmg.a.38830CrossRefPubMed

87.

Wang L, Zhai Q, Zhao P, Xiang X, Zhang X, Tian W, Li T (2018) Functional analysis of p.Ala253_Leu254insAsn mutation in PLS3 responsible for X-linked osteoporosis. Clin Genet. 93(1):178–181. https://doi.org/10.1111/cge.13081CrossRefPubMed

88.

Lv F, Ma M, Liu W, Xu X, Song Y, Li L, Jiang Y, Wang O, Xia W, Xing X, Qiu Z, Li M (2017) A novel large fragment deletion in PLS3 causes rare X-linked early-onset osteoporosis and response to zoledronic acid. Osteoporos Int 28(9):2691–2700. https://doi.org/10.1007/s00198-017-4094-0CrossRefPubMed

89.

Kannu P, Mahjoub A, Babul-Hirji R, Carter MT, Harrington J (2017) PLS3 mutations in X-linked osteoporosis: clinical and bone characteristics of two novel mutations. Horm Res Paediatr 88(3–4):298–304. https://doi.org/10.1159/000477242CrossRefPubMed

90.

van de Laarschot DM, Zillikens MC (2016) Atypical femur fracture in an adolescent boy treated with bisphosphonates for X-linked osteoporosis based on PLS3 mutation. Bone 91:148–151. https://doi.org/10.1016/j.bone.2016.07.022CrossRefPubMed

91.

Nguyen HH, van de Laarschot DM, Verkerk AJMH, Milat F, Zillikens MC, Ebeling PR (2018) Genetic risk factors for atypical femoral fractures (AFFs): a systematic review. JBMR Plus 2(1):1–11. https://doi.org/10.1002/jbm4.10024CrossRefPubMedPubMedCentral

92.

Mäkitie RE, Niinimäki T, Suo-Palosaari M, Kämpe A, Costantini A, Toiviainen-Salo S, Niinimäki J, Mäkitie O (2020) PLS3 mutations cause severe age and sex-related spinal pathology. Front Endocrinol (Lausanne) 23(11):393. https://doi.org/10.3389/fendo.2020.00393CrossRef

93.

Tanaka-Kamioka K, Kamioka H, Ris H, Lim SS (1998) Osteocyte shape is dependent on actin filaments and osteocyte processes are unique actin-rich projections. J Bone Miner Res 13(10):1555–1568. https://doi.org/10.1359/jbmr.1998.13.10.1555CrossRefPubMed

94.

Thouverey C, Malinowska A, Balcerzak M, Strzelecka-Kiliszek A, Buchet R, Dadlez M, Pikula S (2011) Proteomic characterization of biogenesis and functions of matrix vesicles released from mineralizing human osteoblast-like cells. J Proteomics 74(7):1123–1134. https://doi.org/10.1016/j.jprot.2011.04.005CrossRefPubMed

95.

Mäkitie RE, Hackl M, Weigl M, Frischer A, Kämpe A, Costantini A, Grillari J, Mäkitie O (2020) Unique, gender-dependent serum microrna profile in PLS3 gene-related osteoporosis. J Bone Miner Res 35(10):1962–1973. https://doi.org/10.1002/jbmr.4097CrossRefPubMed

96.

Yorgan TA, Sari H, Rolvien T, Windhorst S, Failla AV, Kornak U, Oheim R, Amling M, Schinke T (2020) Mice lacking plastin-3 display a specific defect of cortical bone acquisition. Bone 130:115062. https://doi.org/10.1016/j.bone.2019.115062CrossRefPubMed

97.

Royen PM, Ozonoff MB (1974) Multiple calvarial “doughnut lesions.” Am J Roentgenol Radium Ther Nucl Med 121(1):121–123. https://doi.org/10.2214/ajr.121.1.121CrossRefPubMed

98.

Pekkinen M, Terhal PA, Botto LD, Henning P, Mäkitie RE, Roschger P, Jain A, Kol M, Kjellberg MA, Paschalis EP, van Gassen K, Murray M, Bayrak-Toydemir P, Magnusson MK, Jans J, Kausar M, Carey JC, Somerharju P, Lerner UH, Olkkonen VM, Klaushofer K, Holthuis JC, Mäkitie O (2019) Osteoporosis and skeletal dysplasia caused by pathogenic variants in SGMS2. JCI Insight 4(7):e126180. https://doi.org/10.1172/jci.insight.126180CrossRefPubMedCentral

99.

Robinson ME, Bardai G, Veilleux LN, Glorieux FH, Rauch F (2020) Musculoskeletal phenotype in two unrelated individuals with a recurrent nonsense variant in SGMS2. Bone 134:115261. https://doi.org/10.1016/j.bone.2020.115261CrossRefPubMed

100.

Manousaki D, Kämpe A, Forgetta V, Makitie RE, Bardai G, Belisle A, Li R, Andersson S, Makitie O, Rauch F, Richards JB (2020) Increased burden of common risk alleles in children with a significant fracture history. J Bone Miner Res 35(5):875–882. https://doi.org/10.1002/jbmr.3956CrossRefPubMed

101.

Rocha-Braz MGM, França MM, Fernandes AM, Lerario AM, Zanardo EA, de Santana LS, Kulikowski LD, Martin RM, Mendonca BB, Ferraz-de-Souza B (2020) Comprehensive genetic analysis of 128 candidate genes in a cohort with idiopathic, severe, or familial osteoporosis. J Endocr Soc 4(12):bvaa148. https://doi.org/10.1210/jendso/bvaa148CrossRefPubMedPubMedCentral

102.

Peris P, Monegal A, Martinez MA, Moll C, Pons F, Guanabens N (2007) Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis. Clin Rheumatol 26(6):958–961CrossRefPubMed

103.

Islam MZ, Shamim AA, Viljakainen HT, Akhtaruzzaman M, Jehan AH, Khan HU et al (2010) Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention. Br J Nutr 104(2):241–247CrossRefPubMed

104.

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9(9):840–849CrossRefPubMed

105.

Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE, Joint IOF-ECTS GIO Guidelines Working Group (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23(9):2257–2276. https://doi.org/10.1007/s00198-012-1958-1CrossRefPubMed

106.

Laroche M, Talibart M, Cormier C, Roux C, Guggenbuhl P, Degboe Y (2017) Pregnancy-related fractures: a retrospective study of a French cohort of 52 patients and review of the literature. Osteoporos Int 28(11):3135–3142CrossRefPubMed

107.

Hong N, Kim JE, Lee SJ, Kim SH, Rhee Y (2018) Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis. Clin Endocrinol (Oxf) 88(5):652–658CrossRef

108.

Sokal A, Elefant E, Leturcq T, Beghin D, Mariette X, Seror R (2019) Pregnancy and newborn outcomes after exposure to bisphosphonates: a casecontrol study. Osteoporos Int 30(1):221–229CrossRefPubMed

109.

Langdahl BL (2017) Osteoporosis in premenopausal women. Curr Opin Rheumatol 29(4):410–415CrossRefPubMed

110.

Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD, Abrahamsen B, McCloskey E, Hofbauer LC, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Pepe J, Palermo A, Langdahl B (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgaa756CrossRefPubMed

Title: Early-Onset Osteoporosis
Authors: Outi Mäkitie
M. Carola Zillikens
Publication date: 01-05-2022
Publisher: Springer US
Keywords: Osteoporosis
Osteoporosis
Osteogenesis Imperfecta
Published in: Calcified Tissue International / Issue 5/2022
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-021-00885-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2022

Anorexia Nervosa and Osteoporosis

Disuse Osteoporosis: Clinical and Mechanistic Insights

Osteoporosis and HIV Infection

“Pregnancy and Lactation Associated Osteoporosis”

Impact of Low Energy Availability on Skeletal Health in Physically Active Adults

Osteoporosis and Bone Health in Transgender Individuals

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage